• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE (EBV)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PULMONX CORPORATION ZEPHYR ENDOBRONCHIAL VALVE (EBV) Back to Search Results
Model Number ZEPHYR 4.0-LP EBV
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problem Pneumothorax (2012)
Event Date 09/30/2019
Event Type  Injury  
Manufacturer Narrative
Pneumothorax is the most common side effect associated with the zephyr valve treatment (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).Targeted lobar deflation likely causes inflation of the ipsilateral lobe, which can result in a tear of the already compromised parenchymal tissue of the emphysematous ipsilateral lobe, resulting in a pneumothorax (criner et al.A multicenter randomized controlled trial of zephyr endobronchial valve treatment in heterogeneous emphysema (liberate).Am j respir crit care med.2018; 198 (9): 1151-1164).In the liberate study (ide clinical study used to support pma p180002's approval), 26.6% of the zephyr valve subjects experienced a pneumothorax in the treatment period (less than or equal to 45 days).These were managed using standard of care procedures as per previously published guidelines (valipour, arschang, et al.Respiration 87.6 (2014): 513-521).In 17.4% of the events, the pneumothorax resolved without any additional intervention with subjects under careful observation.In over half the events (56.5%), the pneumothorax was managed with a chest-tube only.An additional 13% of the events were managed with a chest-tube and the temporary removal of one or more valves, while another 13% of the events were managed with a chest-tube and removal of all the implanted valves.Upon successful resolution of the pneumothorax, removed valves can be replaced.Patients that experienced a pneumothorax experienced clinical benefits of the zephyr valve treatment that were similar to the benefits experienced by patients who did not have a pneumothorax.The zephyr ebv system ifu and pulmonx training program both specifically reference pneumothorax as a known side effect of this procedure and the published guidelines (valipour, arschang, et al."expert statement: pneumothorax associated with endoscopic valve therapy for emphysema-potential mechanisms, treatment algorithm, and case examples." respiration 87.6 (2014): 513-521).The reported event aligns with the experience observed in the (b)(6) clinical study and is an expected side effect to the zephyr valve treatment.
 
Event Description
On (b)(6) 2019, patient underwent bronchoscopic procedure and had five zephyr endobronchial valves (four 4.0 ebvs, one 4.0-lp ebv) placed in the left lower lobe based on ct reading of negative collateral ventilation in the left upper lobe.The physician placed a chest tube in the patient immediately post-procedure due to his plan of preemptively placing chest tubes in valve patients until there are adequate processes in place at the hospital to handle chest tube placements during a given valve patient's 3-day inpatient stay.The patient developed a pneumothorax later in the day.On (b)(6) 2019, the chest tube was removed.On (b)(6) 2019, the lung expanded and the patient was discharged.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ZEPHYR ENDOBRONCHIAL VALVE (EBV)
Type of Device
ENDOBRONCHIAL VALVE
Manufacturer (Section D)
PULMONX CORPORATION
700 chesapeake drive
redwood city CA 94063
Manufacturer Contact
leland keyt
700 chesapeake drive
redwood city, CA 94063
6502160144
MDR Report Key9279593
MDR Text Key167772324
Report Number3007797756-2019-00165
Device Sequence Number1
Product Code NJK
UDI-Device Identifier00811907030225
UDI-Public(01)00811907030225(10)504362V71(17)210508
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P180002
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Non-Healthcare Professional
Remedial Action Patient Monitoring
Type of Report Initial
Report Date 11/05/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/05/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date05/08/2021
Device Model NumberZEPHYR 4.0-LP EBV
Device Catalogue NumberEBV-TS-4.0-LP
Device Lot Number504362-V7.1
Was Device Available for Evaluation? No
Date Manufacturer Received10/08/2019
Was Device Evaluated by Manufacturer? No
Date Device Manufactured05/08/2019
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age65 YR
Patient Weight86
-
-